Clinical Trials on Neurogenic Bladder, Uninhibited in Belgium

Total 136 results

University of Zurich

Recruiting

Bladder and TranscUtaneous Tibial Nerve Stimulation for nEurogenic Lower Urinary Tract Dysfunction (bTUNED)

Neurogenic Bladder Dysfunction

Belgium, Brazil, Italy, Switzerland
Boehringer Ingelheim

Completed

Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder

Bladder, Neurogenic

Belgium, Spain, United States, India, South Africa, Philippines, Italy, Korea, Republic of, Russian Federation, Germany, Brazil, Mexico, Ukraine
Boehringer Ingelheim

Completed

PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder

Bladder, Neurogenic

Belgium, Spain, United States, South Africa, Philippines, Italy, Korea, Republic of, Russian Federation, Germany, India, Brazil, Canada, Mexico, Ukraine
Pfizer

Completed

BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG

Neurogenic Detrusor Overactivity

Belgium
Astellas Pharma Inc

Completed

Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder

Overactive Bladder | Neurogenic Detrusor Overactivity

Belgium, Canada, Denmark, Netherlands, Poland, Turkey, United Kingdom
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Overactive Bladder | Pharmacokinetics of Mirabegron | Neurogenic Detrusor Overactivity

Belgium, Denmark, Norway, Poland, Serbia
Pfizer

Completed

Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulation Administer

Neurogenic Detrusor Overactivity

Belgium
Astellas Pharma Europe B.V.

Completed

A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

Pediatric | Neurogenic Detrusor Overactivity

United States, Belgium, Korea, Republic of, Philippines, Poland, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

Neurogenic Detrusor Overactivity

United States, Belgium, Brazil, Denmark, Hungary, Korea, Republic of, Mexico, Philippines, Poland, Turkey
Allergan

Completed

Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)

Multiple Sclerosis | Urinary Incontinence | Neurogenic Bladder

France, Poland, Portugal, Belgium, Canada, Russian Federation, Czechia, United States
MedtronicNeuro

Terminated

Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder (ACCEPTANCE)

Urinary Incontinence | Detrusor Overactivity | Neurogenic Overactive Bladder

Belgium, France, United Kingdom, Germany, Italy, Netherlands
Astellas Pharma Europe B.V.

Completed

Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (Crocodile)

Neurogenic Detrusor Overactivity

Belgium, Croatia, Turkey, Australia, Denmark, Israel, Jordan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Norway, Philippines, Poland, Romania, Serbia, Slovakia, Taiwan
Astellas Pharma Inc

Completed

Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis (SONIC)

Multiple Sclerosis | Spinal Cord Diseases | Neurogenic Bladder

Australia, France, Belgium, Germany, Netherlands, Italy, Spain, United Kingdom, Hungary, Czechia, Russian Federation
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Mirabegron in Young Children With Neurogenic Detrusor Overactivity

Neurogenic Detrusor Overactivity

Philippines, Turkey, Belgium, Denmark
Pfizer

Completed

A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition

Urinary Bladder, Neurogenic

France, United States, Spain, Korea, Republic of, United Kingdom, Malaysia, Taiwan, Finland, Japan, Lithuania, Italy, Turkey, Estonia, Slovakia, Belgium, Canada, Germany, Greece, India, Philippines, Poland, Russian Federation, South... and more
GlaxoSmithKline

Completed

Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer

Neoplasms, Urinary Bladder

Belgium
University Hospital, Ghent

Completed

External Beam Radiotherapy for Muscle Invasive Bladder Cancer

Toxicity

Belgium
University Hospital, Ghent
Takeda

Completed

Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer.

Prostate or Bladder Cancer

Belgium
Universiteit Antwerpen

Unknown

Sacral Neuromodulation and Pudendal Somatic Afferents

Overactive Bladder, Non Obstructive Urinary Retention

Belgium
University Hospital, Ghent
Astellas Pharma Inc; Medtronic

Completed

Treatment of the Overactive Bladder Syndrome: A Delphi Study

Overactive Bladder Syndrome

Belgium
University Hospital, Ghent

Terminated

TTNS Versus Sham Therapy for Children With iOAB (TaPaS Part I) (TaPaS)

Overactive Bladder Syndrome

Belgium
University Hospital, Ghent
Kom Op Tegen Kanker

Recruiting

Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients With Muscle Invasive Bladder Cancer (EFFORT-MIBC)

Muscle-Invasive Bladder Carcinoma

Belgium
University Hospital, Ghent

Completed

Unmet Supportive Care Needs in Bladder Cancer Patients Undergoing Radical Cystectomy

Surgery | Bladder Cancer | Urologic Cancer

Belgium
University Hospital of Mont-Godinne

Unknown

Rule of Carbone Monoxyde in the Ex Vivo Lung Perfusion Reconditionning

Neurogenic Lung Edema

Belgium
Imelda Hospital, Bonheiden
Universitaire Ziekenhuizen KU Leuven; AZ Sint-Jan AV; Biosense Webster, Inc.; Trium...

Recruiting

Efficacy of a Right-sided Ablation of the Anterior Ganglionated Plexus for Neurally Mediated Syncope (CardNMH3)

Syncope | Syncope, Neurogenic

Belgium
KU Leuven
Agentschap voor Innovatie door Wetenschap en Technologie

Completed

Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer (SELEBLAT)

Bladder Cancer

Belgium
University Hospital, Ghent
Medtronic

Completed

OptiLUTS Part C: The Development of a Symptom Assessment Tool in Sacral Neuromodulation. (OptiLUTS)

Urinary Retention | Fecal Incontinence | Overactive Bladder Syndrome | Dysfunctional Voiding | Fowler Syndrome

Belgium
Universiteit Antwerpen
Leiden University Medical Center

Unknown

Standardization of Lead Placement for Sacral Neuromodulation Part 2

Overactive Bladder | Non Obstructive Urinary Retention

Belgium
University Hospital, Ghent

Active, not recruiting

Adjuvant Radiotherapy After Cystectomy for Muscle Invasive Bladder Cancer

Toxicity

Belgium
Universiteit Antwerpen
Leiden University Medical Center

Unknown

Standardization of Lead Placement for Sacral Neuromodulation. Part 1

Overactive Bladder | Non Obstructive Urinary Retention

Belgium
Universiteit Antwerpen

Unknown

Sacral Neuromodulation & Urodynamics

Overactive Bladder | Non-obstructive Urinary Retention

Belgium
Jessa Hospital

Completed

Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB) (Prophylaxis001)

Bladder Cancer | Antibiotic-associated Diarrhea | Antibiotic Resistant Infection | Antibiotic Resistant Strain | Antibiotic Toxicity | Prostate Hyperplasia | Urosepsis

Belgium
Amphora Medical, Inc.

Terminated

Cystoscopic Ablation Via RF Energy Clinical Trial (CARETI)

Overactive Bladder

Canada, Belgium
Universitair Ziekenhuis Brussel

Completed

Nephrogenic Diabetes Insipidus During Prolonged Sevoflurane Sedation in the ICU: a Retrospective Analysis

Nephrogenic Diabetes Insipidus

Belgium
Amber Therapeutics Ltd

Active, not recruiting

AURA-2: Augmenting Urinary Reflex Activity (AURA-2)

Overactive Bladder | Urge Incontinence

Belgium
National Multiple Sclerosis Center

Terminated

Prospective Trial Comparing Intravesical Chondroitin Sulphate 2% and DMSO in the Treatment of PBS/Interstitial Cystitis

Interstitial Cystitis | Painful Bladder Syndrome

Belgium
University Hospital, Ghent
Algemeen Ziekenhuis Maria Middelares; AZ Sint-Lucas Gent; AZ Jan Palfijn Gent

Not yet recruiting

Diversity in Patients With OAB (DOAB)

Overactive Bladder | Sacral Neuromodulation | Diversity | Onabotulinum Toxin A | Discrete Choice Experiment

Belgium
Axonics Modulation Technologies, Inc.

Completed

Treatment of REfractory Overactive BLadder With the AXonics Sacral Neuromodulation System (RELAX-OAB) (RELAX-OAB)

Overactive Bladder

Netherlands, France, Belgium, United Kingdom
Universiteit Antwerpen

Recruiting

What is the Effect of Prolapse Surgery on Voiding? (PROVOID)

Overactive Bladder | Voiding Disorders | Pelvic Organ Prolapse | Stress Urinary Incontinence | Urge Incontinence

Belgium
Jules Bordet Institute
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial) (AURA)

Non-metastatic Muscle Invasive Bladder Cancer

France, Belgium
Astellas Pharma Europe B.V.
Veeda Clinical Research

Completed

Treatment of Symptoms in Male Patients With Lower Urinary Tract Symptoms (LUTS) Predominant Storage Symptoms (Overactive Bladder Syndrome) (VENICE)

Lower Urinary Tract Predominant Storage Symptoms

Belgium
Association Pour La Recherche des Thérapeutiques...
Roche Pharma AG

Completed

Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma (CVH-CT02)

Recurrent Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder

France, Belgium
Universitaire Ziekenhuizen KU Leuven
KU Leuven

Recruiting

Prospective Sample Collection for Cancer of Bladder (ProCaB)

Urinary Bladder Neoplasms

Belgium
European Organisation for Research and Treatment...

Terminated

Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer

Bladder Cancer

Netherlands, Belgium, Italy, Turkey, Slovakia
Universiteit Antwerpen

Recruiting

Comparison of a Paper and Automated Bladder Diary in Pediatric Patients

Overactive Bladder | Lower Urinary Tract Symptoms | Enuresis | Voiding Disorders

Belgium
Allergan

Completed

Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

Overactive Bladder

Poland, United Kingdom, Belgium, Russian Federation, Czech Republic, Germany, United States
Allergan

Completed

A Research Study for Patients With Overactive Bladder

Overactive Bladder | Urinary Incontinence

Poland, Germany, United States, Canada, United Kingdom, Belgium
Astellas Pharma Inc

Completed

Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents

Urinary Bladder, Overactive

Sweden, United Kingdom, Belgium, Denmark
Vitadx
FONDATION FORCE POUR L'INNOVATION ET LA RECHERCHE EN SANTE

Recruiting

Demonstration of the Medical Interest of the VisioCyt® Artificial Intelligence Test (DMIA)

Non-muscle Invasive Bladder Cancer (NMIBC)

France, Belgium, Spain
European Organisation for Research and Treatment...

Completed

BCG With or Without Mitomycin in Treating Patients With Bladder Cancer

Bladder Cancer

Netherlands, Belgium, United Kingdom, Italy, Portugal, Turkey

Clinical Trials on Neurogenic Bladder, Uninhibited in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations